Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
PURPOSE: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country.
METHODS: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians' request in the clinical care for therapy decisions. Kaplan-Meier survival curves were estimated to characterize the time-to-event variables.
RESULTS: Patients median age was 61 years (range: 14-87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P = .7).
CONCLUSION: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Cancer control : journal of the Moffitt Cancer Center - 30(2023) vom: 06. Jan., Seite 10732748231175256 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cifuentes, Claudia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Actionable mutations |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 10.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/10732748231175256 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356514757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356514757 | ||
| 003 | DE-627 | ||
| 005 | 20231226070627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10732748231175256 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356514757 | ||
| 035 | |a (NLM)37148308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cifuentes, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 10.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country | ||
| 520 | |a METHODS: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians' request in the clinical care for therapy decisions. Kaplan-Meier survival curves were estimated to characterize the time-to-event variables | ||
| 520 | |a RESULTS: Patients median age was 61 years (range: 14-87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P = .7) | ||
| 520 | |a CONCLUSION: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a actionable mutations | |
| 650 | 4 | |a comprehensive genomic profiling | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a precision medicine | |
| 700 | 1 | |a Lombana, Milton |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Laguado, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Patiño, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Uriel |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ricaurte, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Arrieta, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Zatarain-Barron, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata, Leandro |e verfasserin |4 aut | |
| 700 | 1 | |a González, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Restrepo, Juan G |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Grosso, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Mantilla, William |e verfasserin |4 aut | |
| 700 | 1 | |a Carranza, Hernán |e verfasserin |4 aut | |
| 700 | 1 | |a Bustillo, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Llinas, Néstor |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, July |e verfasserin |4 aut | |
| 700 | 1 | |a Archila, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Ávila, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Bermúdez, Maritza |e verfasserin |4 aut | |
| 700 | 1 | |a Gámez, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Sotelo, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Otero, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Forero, Elkin |e verfasserin |4 aut | |
| 700 | 1 | |a Lema, Mauricio |e verfasserin |4 aut | |
| 700 | 1 | |a Limpias, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Ordóñez-Reyes, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Mejía, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfo, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Rosell, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Cardona, Andrés F |e verfasserin |4 aut | |
| 700 | 0 | |a ONCOL Group |e verfasserin |4 aut | |
| 700 | 0 | |a CLICaP |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer control : journal of the Moffitt Cancer Center |d 1994 |g 30(2023) vom: 06. Jan., Seite 10732748231175256 |w (DE-627)NLM093817053 |x 1526-2359 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g day:06 |g month:01 |g pages:10732748231175256 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10732748231175256 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |b 06 |c 01 |h 10732748231175256 | ||